Sankyo Selected Evotec as Assay Development and Screening
News Apr 28, 2006
Evotec will apply their skills and proprietary technologies in assay development and ultra-high throughput screening (uHTS) to identify biologically active molecules from its corporate library that interact with disease targets selected by Sankyo.
Compounds identified in screening will be further characterised and prioritised by Evotec for progression into Sankyo’s subsequent lead optimisation programmes.
Dr Mark Ashton, Executive Vice President Business Development Services at Evotec, said, "We are delighted and proud that Sankyo, one of the largest pharmaceutical companies in Japan, has selected us for these important drug finding projects."
"We enjoyed the constructive and open discussions during the planning phase of this collaboration. These projects represent another important milestone in strengthening our collaborative relationships with pharmaceutical companies in Japan."
"This project is an important extension of our lead discovery activities, and we appreciate Evotec's technological capabilities as well as the commitment to the project."
"We already enjoyed the atmosphere of mutual respect and believe that this collaboration will be successful," commented Dr Hideyuki Haruyama, Corporate Officer and General Manager, Research Institute at Sankyo.
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019